Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes.

about

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes.

Item

http://www.wikidata.org/entity/Q48189728

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Comparison of Exenatide and Me ...... wly Diagnosed Type 2 Diabetes.

@en

Comparison of Exenatide and Me ...... wly Diagnosed Type 2 Diabetes.

@nl

type

Item

label

Comparison of Exenatide and Me ...... wly Diagnosed Type 2 Diabetes.

@en

Comparison of Exenatide and Me ...... wly Diagnosed Type 2 Diabetes.

@nl

prefLabel

Comparison of Exenatide and Me ...... wly Diagnosed Type 2 Diabetes.

@en

Comparison of Exenatide and Me ...... wly Diagnosed Type 2 Diabetes.

@nl

P1476

Comparison of Exenatide and Me ...... ewly Diagnosed Type 2 Diabetes

@en

P2093

Li Miao

http://www.w3.org/2001/XMLSchema#string

Yanjin Hu

http://www.w3.org/2001/XMLSchema#string

Yuan Xu

http://www.w3.org/2001/XMLSchema#string

Yumei Jia

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Incretin physiology and pathophysiology from an Asian perspective

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Standards of medical care in diabetes--2013

Internet interventions to support lifestyle modification for diabetes management: a systematic review of the evidence.

MARCH2: comparative assessment of therapeutic effects of acarbose and metformin in newly diagnosed type 2 diabetes patients

Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass.

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

P304

9401606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2017/9401606

http://www.w3.org/2001/XMLSchema#string

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

Guang Wang

Jia Liu

P577

2017-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29358950

http://www.w3.org/2001/XMLSchema#string

P921

Adipositas

metformin

type-2 diabetes

P932

5735665

http://www.w3.org/2001/XMLSchema#string